BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Bioheart announces clinical result for Iberis-HTN at CIT 2023

Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate the safety and efficacy of the Iberis® Multi-Electrode...

June 30, 2023 | News

AI-Designed Drug Enters Phase II Trials, First Patients Dosed by Insilico Medicine

After completing the Phase 0 and Phase I human safety studies, INS018_055, Insilico's AI-discovered and AI-generated drug, has ent...

June 28, 2023 | News

Innovent and RemeGen Collaborate on Clinical Trial for Combined Therapy of TYVYT® and Novel ADCs in China

Under the agreement, Innovent will provide clinical drug supplies of TYVYT® (sintilimab injection) during the clinical trial collaboration. RemeGen wil...

June 26, 2023 | News

Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharmaceuticals to Develop a Novel Cancer Therapeutic

The Lubrizol Corporation announces the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The licen...

June 23, 2023 | News

Everest Medicines' Partner Calliditas Presents Nefecon Data at ERA-EDTA Congress

The presentations showed data and analyses from the NefIgArd Phase 3 clinical trial evaluating Nefecon in patients with IgA nephropathy (IgAN). The study m...

June 21, 2023 | News

Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval

Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase...

June 21, 2023 | News

Sirnaomics Advances STP705 for SCCIS into Late-Stage Clinical Development

The FDA provided Sirnaomics guidance to move forward with late-stage clinical development because of the efficacious data provided as well as the widesprea...

June 20, 2023 | News

Curocell Announces Positive Updates on Next-Gen Anti-CD19 CAR-T at ICML 2023

84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relap...

June 20, 2023 | News

FDA Approves Phase I/II Trial for Leads Biolabs' Anti-MUC16/CD3 Bispecific Antibody in Advanced Solid Tumors.

The study is a multicenter, open-label, dose-escalation and expansion phase Ⅰ/Ⅱ clinical study. The phase Ⅰ part aims to evaluate the safety, to...

June 19, 2023 | News

FDA Approves Utidelone Injectable (UTD1) Trial for Non-Small Cell Lung Cancer

Designated as BG01-2202, this trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable (UTD1) v...

June 16, 2023 | News

MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China

"The initiation of our FIH clinical trial with MDR-001 is an important milestone for MindRank which is yet another great validation of the potential of our...

June 15, 2023 | News

Biostar Pharma Enrolls First Patient for Phase 1 Study of UTD2, World's First Oral Epothilone Anti-Cancer Drug

This study will be conducted at multiple clinical research centers including Sarah Cannon Research Institute (Florida Cancer Specialists & Research Ins...

June 13, 2023 | News

Eccogene Raises CNY 180M in Series B Financing for Metabolic Disease Treatments

Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, announced a CNY 1...

June 12, 2023 | News

Dizal Highlights Oncology Pipeline Strength at 2023 ASCO, Leading China's Biotech Innovation

Two highly anticipated oral presentations captured attention: first pivotal study of sunvozertinib (WU-KONG6) and multinational pivotal study of golidoci...

June 08, 2023 | News

Stay Connected